 |
| Tanisha Carino |
Brunswick Group has hired Tanisha Carino, who has more than 20 years of healthcare and life sciences experience, as a partner in its Washington office.
She served as executive VP & chief corporate affairs officer at Alexion Pharmaceuticals, which was an independent Fortune 500 biotechnology company focused on rare diseases.
Carino handled global PR, policy and alliance development at Alexion. She also guided the company's communications through its acquisition by AstraZeneca.
Earlier, she was executive director of the Milken Institute's FasterCure operation, VP-US public policy at GlaxoSmithKline and head of life sciences strategic advisory services at Avalere Health.
Most recently, Carino was a visiting fellow at the White House Office of Science and Technology Policy, working in the area of pandemic preparedness.
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
